纳米颗粒与干扰RNA结合,作为胰腺癌治疗方法:系统性审查
Patricia Lara1, Francisco Quiñonero2, Raul Ortiz1,2
1Institute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), Granada, Spain.
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
|November 7, 2024
概括
装有小干扰RNA (siRNA) 的纳米颗粒显示出治疗胰腺癌的重大前景. 这种创新方法将纳米技术与基因疗法结合起来,以克服治疗耐药性并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 纳米技术 纳米技术
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰腺癌的预后不好,原因是诊断迟到,耐药性和有效治疗方法有限.
- 新型药理学策略对于提高患者存活率至关重要.
- 纳米粒子为治疗剂提供了高效的输送系统.
研究的目的:
- 在过去的十年里,系统地审查关于纳米粒子-siRNA在胰腺癌中的应用的文献.
- 评估将纳米技术与小干扰RNA (siRNA) 结合用于胰腺癌治疗的有效性.
主要方法:
- 在PubMed,Scopus和Web of Science数据库中进行的系统文献审查.
- 从最初的164项已识别的研究中选择了37篇相关文章.
- 专注于研究利用装载siRNA的纳米颗粒用于胰腺癌治疗.
主要成果:
- 纳米粒子和siRNA的组合在临床前和临床胰腺癌模型中表现出高效.
- 这种治疗策略显示出克服胰腺瘤特征的治疗耐药性的潜力.
- 在这种情况下,大量的研究突出了基于siRNA的药物的疗效.
结论:
- 纳米粒子-siRNA结合物代表了胰腺癌的有希望的新疗法策略.
- 这种方法有可能彻底改变胰腺癌的治疗方法,开启基因疗法的新时代.
- 基于siRNA的药物的进一步开发和临床转化是有必要的.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K